Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561053 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by Instituto Grifols, S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 347
- Enrollment target
- 20
- Study locations
NCT01561053 is a Phase 2 study of Alzheimers Disease that has completed, run by Instituto Grifols, S.A.. The registered enrollment target is 347 participants, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT01561053, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Instituto Grifols, S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 347 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
Conditions Studied
Interventions
- BIOLOGICAL Albumin 5%
- BIOLOGICAL Albumin 20%
- BIOLOGICAL Immunoglobulin
Study Locations (20)
Florida
- Bradenton Research Center, Inc. - Bradenton
- Quantum Laboratories - Deerfield Beach
- Galiz Research, LLC - Hialeah
- Largo Medical Center - Largo
- L&L Research Choices, Inc - Miami
- Allied Biomedical Research Institute - Miami
- Miami Dade Medical Research Institute, LLC - Miami
- Neurology Associates of Osmond Beach - Ormond Beach
- PharmaSeek LLC (DMI Research) - Pinellas Park
Georgia
- iResearch Atlanta, LLC - Decatur
- RTR Medical Group - Savannah
New Jersey
- The NeuroCognitive Institute - Mount Arlington
- Mid-Atlantic Geriatric/ARC - Paterson
Ohio
- The Cleveland Clinic Foundation - Cleveland
- Neurology Specialists Inc - Dayton
California
- Northern California Research - Sacramento
Colorado
- Mountain View Clinical Research, Inc - Denver
District of Columbia
- Howard University - Washington D.C.
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2012-04-19 |
| Est. Completion | 2018-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01561053
The ClinicalTrials.gov registry entry for NCT01561053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (91% lower). The listed sponsor is Instituto Grifols, S.A., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 3 interventions - of which Albumin 5% is the first listed.
NCT01561053 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Georgia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01561053 about?
NCT01561053 is a clinical study titled "A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease". The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
What is the current status of trial NCT01561053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 347 participants. The study started on 2012-04-19. Estimated completion is 2018-03-06.
What conditions does trial NCT01561053 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01561053?
The interventions under investigation include: Albumin 5% (BIOLOGICAL), Albumin 20% (BIOLOGICAL), Immunoglobulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT01561053?
This trial is sponsored by Instituto Grifols, S.A., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01561053 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.